The latest Consumer Price Index was below what economists had expected and likely reflects what they called distortions caused by the government shutdown. Note: Data for October 2025 is missing ...
The Swiss economy shrank in the third quarter at the sharpest rate since the depths of the Covid-19 pandemic in 2020. The government attributed the contraction largely to a plunge in output from the ...
BCK Capital opened a new stake in Chart Industries, buying 20,628 shares that accounted for 4.4% of its AUM at the end of Q3. Post-trade, the fund holds 20,628 GTLS shares valued at $4.13 million. The ...
At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial. The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg ...
WARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has ...
The most recently published U.S. Agriculture Department data shows that as of 2023, the largest group of Supplemental Nutrition Assistance Program recipients by race was white (35.4%), followed by ...
iCenter for Paediatric Endocrinology, Diabetology, and Clinical Research, Auf Der Bult Children's Hospital, Hannover, Germany jDepartment of Endocrinology, Diabetes, and Metabolic Diseases, University ...
The U.S. economy grew at a strong 3.8% annualized pace in the second quarter, the government reported Thursday in its final revision of gross domestic product data for April through June. U.S. GDP — ...
iTaperloc® Complete and iG7™ Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint ...
Investors may be surprised to see a comparison between BYD and Tesla. BYD can arguably be called the global EV leader even over Tesla. The Chinese company generates more revenue than Tesla, and it is ...
Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results